Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

A. Hurvitz, Sara; Martin, Miguel; F. Press, Michael; Chan, David; Fernandez-Abad, María; Petru, Edgar; Rostorfer, Regan; Guarneri, Valentina; Huang, Chiun-Sheng; Barriga, Susana; Wijayawardana, Sameera; Brahmachary, Manisha; J. Ebert, Philip; Hossain, Anwar; Liu, Jiangang; Abel, Adam; Aggarwal, Amit; M. Jansen, Valerie; J. Slamon, Dennis

doi:10.1158/1078-0432.ccr-19-1425

Public

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Shared by NobleBlocks on Feb 1, 2020 • 12:00 AM UTC

Authors:

Sara A. Hurvitz

Miguel Martin

Michael F. Press

Abstract

Abstract Purpose: neoMONARCH assessed the biological effects of abemaciclib in combination with anastrozole in the neoadjuvant setting. Patients and Methods: Postmenopausal women with stage I–IIIB HR+/HER2− breast cancer were randomized to a 2-week lead-in of abemaciclib, anastrozole, or abemaciclib...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!